製品名:2-[(1R,3aS,3bS,9aS,9bR,11aS)-9b-bromo-1,10-dihydroxy-2,9a,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethyl acetate

IUPAC Name:2-[(1R,3aS,3bS,9aS,9bR,11aS)-9b-bromo-1,10-dihydroxy-2,9a,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethyl acetate

CAS番号:13796-49-1
分子式:C24H31BrO6
純度:95%+
カタログ番号:CM1046906
分子量:495.41

包装単位 有効在庫 価格(USD) 数量

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:13796-49-1
分子式:C24H31BrO6
融点:-
SMILESコード:CC1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3(C(C[C@@]2([C@]1(C(=O)COC(=O)C)O)C)O)Br)C
密度:
カタログ番号:CM1046906
分子量:495.41
沸点:
MDL番号:
保管方法:

Column Infos

Vamorolone
Dec 18, 2023, AGAMREE (vamorolone) has been approved in the European Union (EU) for the treatment of DMD in patients 4 years of age and older.
Duchenne muscular dystrophy (DMD) is a genetic muscle disease. And The feature is contraction-induced myofibre injury and inflammation. Researchers found that NF-κB signaling is active in dystrophin deficient muscle. Therefore, Inhibiting NF-κB is a potent strategy for the treatment of DMD. Vamorolone is an investigational drug that was developed as a novel dissociative steroidal anti-inflammatory. This means that its chemical profile is such that it shows chemical separation of efficacy (clinical benefit) from some safety concerns (side effect profiles) typically seen with corticosteroids. 
AGAMREE is the only approved medication in the EU for treating DMD, and the first DMD treatment approved in both the U.S. and EU.